For the record, not endorsing. It seems to me to be a strange balance between enough possibility of good to allow it to be administered, but not enough support to fully research and resolve it. I mean..there are treatments that are not allowed period. What is that threshold? Regarding the issue of funding for trials in alternative medicine, there are folks at MD Anderson pointing to the problem as well. But...you would think if ther ewas something to it, there would be investors wanting to buy into the antineoplastons, assuming they or th etreatment are patentable.
I figured with those ongoing issues and a film coming out this would be of interest.
There's a discussion here:
http://www.cancercompass.com/message...ll,11027,0.htm
Quackwatch link:
http://www.quackwatch.org/01Quackery...OTA/ota05.html
Regarding FDA, from the cancer.gov link:
Quote:
|
In 1991, the National Cancer Institute (NCI) reviewed some of Dr. Burzynski’s cases and decided to conduct clinical trials on antineoplastons at cancer centers. By August 1995, only 9 patients had enrolled and the clinical trials were closed before being completed. The U. S. Food and Drug Administration (FDA) gave Dr. Burzynski permission to conduct clinical trials of antineoplaston therapy at his own clinic. Ongoing non-randomized clinical trials at the Burzynski clinic continue to study the effect of antineoplastons on cancer.
|
The .gov page refers to the side effects in the phase II trial. Here is the pubmed abstract:
Drugs R D. 2003;4(2):91-101.
Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic brain stem glioma: a preliminary report.
Burzynski SR,
Lewy RI,
Weaver RA,
Axler ML,
Janicki TJ,
Jurida GF,
Paszkowiak JK,
Szymkowski BG,
Khan MI,
Bestak M.
Department of Internal Medicine, Burzynski Clinic, Houston, Texas, USA.
info@burzynskiclinic.com
OBJECTIVE: A phase II study of antineoplaston A10 and AS2-1 was conducted to evaluate the antineoplastic activity in patients with recurrent diffuse intrinsic brain stem glioma. PATIENTS AND METHODS: This report describes the results of treatment of the first 12 patients admitted to the study. Patients received escalating doses of antineoplaston A10 and AS2-1 by intravenous bolus injections. The median duration of treatment was 6 months and the average dosage of antineoplaston A10 was 11.3 g/kg/day and of antineoplaston AS2-1 0.4 g/kg/day. Responses were assessed by gadolinium-enhanced magnetic resonance imaging of the head. RESULTS: Of ten evaluable patients, complete response was determined in two cases (20%), partial response in three (30%), stable disease in three (30%) and progressive disease in two (20%). Survival at 2 years was 33.3%. Currently, of all 12 patients, two (17%) were alive and tumour free for over 5 years since initial diagnosis; one was alive for more than 5 years, and another for more than 4 years from the start of treatment. Only mild and moderate toxicities were observed, which included three cases of skin allergy, two cases of anaemia, fever and hypernatraemia, and single cases of agranulocytosis, hypoglycaemia, numbness, tiredness, myalgia and vomiting. CONCLUSION: The results of this study compared favourably with the responses of patients treated with radiation therapy and chemotherapy. The study continues with accrual of additional patients.
PMID: 12718563 [PubMed - indexed for MEDLINE]
Here are the more recent pubmed abstracts:
Targeted therapy with antineoplastons A10 and AS2-1 of high-grade, recurrent, and progressive brainstem glioma.
Burzynski SR, Janicki TJ, Weaver RA, Burzynski B.
Integr Cancer Ther. 2006 Mar;5(1):40-7.PMID: 16484713 [PubMed - indexed for MEDLINE]
Related articles
3.
Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with antineoplastons A10 and AS2-1.
Burzynski SR, Weaver RA, Janicki T, Szymkowski B, Jurida G, Khan M, Dolgopolov V.
Integr Cancer Ther. 2005 Jun;4(2):168-77.PMID: 15911929 [PubMed - indexed for MEDLINE]
Related articles
4.
Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma : a preliminary report.
Burzynski SR, Weaver RA, Lewy RI, Janicki TJ, Jurida GF, Szymkowski BG, Khan MI, Bestak M.
Drugs R D. 2004;5(6):315-26.PMID: 15563234 [PubMed - indexed for MEDLINE]
Related articles